Nancy Lurker Eye Point Pharmaceuticals, Inc. (EYPT) insider trading activity

Nancy Lurker is of EyePoint Pharmaceuticals, Inc.. Currently has a direct ownership of 216,547 shares of EYPT, which is worth approximately $2.29 Million. The most recent transaction as insider was on Jul 10, 2025, when has been sold 11,111 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 217K

5.41% 3M change

129.24% 12M change

Total Value Held $2.29 Million

Nancy Lurker Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 10 2025	BUY Exercise of conversion of derivative security	-	11,111 Added 4.88%	216,547 Common Stock
Feb 09 2025	BUY Exercise of conversion of derivative security	-	20,000 Added 8.87%	205,436 Common Stock
Jan 06 2025	BUY Exercise of conversion of derivative security	-	75,134 Added 28.83%	185,436 Common Stock
Jan 05 2025	BUY Exercise of conversion of derivative security	-	12,667 Added 10.3%	110,302 Common Stock
Aug 16 2024	BUY Open market or private purchase	$25,003 $7.88 p/Share	3,173 Added 3.15%	97,635 Common Stock
Jul 10 2024	BUY Exercise of conversion of derivative security	-	11,111 Added 10.52%	94,462 Common Stock
Feb 13 2024	SELL Bona fide gift	-	74,681 Reduced 47.26%	83,351 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$430,358 $28.8 p/Share	14,943 Reduced 8.64%	158,032 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	37,534 Added 17.83%	172,975 Common Stock
Jan 24 2024	SELL Open market or private sale	$748,300 $24.98 p/Share	29,956 Reduced 18.11%	135,441 Common Stock
Jan 23 2024	SELL Open market or private sale	$125,948 $24.97 p/Share	5,044 Reduced 2.96%	165,397 Common Stock
Jan 06 2024	SELL Payment of exercise price or tax liability	$470,077 $20.4 p/Share	23,043 Reduced 11.91%	170,441 Common Stock
Jan 06 2024	BUY Exercise of conversion of derivative security	-	75,133 Added 27.97%	193,484 Common Stock
Dec 04 2023	SELL Open market or private sale	$415,200 $20.76 p/Share	20,000 Reduced 10.5%	170,559 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	-	37,533 Added 16.46%	190,559 Common Stock
Feb 28 2022	BUY Exercise of conversion of derivative security	-	12,466 Added 7.66%	150,281 Common Stock
Feb 21 2022	BUY Exercise of conversion of derivative security	-	13,717 Added 9.05%	137,815 Common Stock
Feb 09 2022	BUY Exercise of conversion of derivative security	-	17,533 Added 12.38%	124,098 Common Stock
Nov 15 2021	SELL Open market or private sale	$201,500 $20.15 p/Share	10,000 Reduced 8.81%	103,546 Common Stock
Jun 14 2021	BUY Exercise of conversion of derivative security	-	4,500 Added 3.81%	113,546 Common Stock
Feb 28 2021	BUY Exercise of conversion of derivative security	-	12,467 Added 10.26%	109,046 Common Stock
Feb 21 2021	BUY Exercise of conversion of derivative security	-	13,717 Added 12.44%	96,579 Common Stock

Also insider at

ALKS

Alkermes plc. Healthcare

Director

COLL

COLLEGIUM PHARMACEUTICAL, INC Healthcare

Director

AQST

Aquestive Therapeutics, Inc. Healthcare

Nancy Lurker

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EYPT shares.

Notify only if

Value

Insider Trading

Get notified when an Eye Point Pharmaceuticals, Inc. insider buys or sells EYPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to EyePoint Pharmaceuticals, Inc.

Track Activities on EYPT

Account